FluroTech (TSXV:TEST,OTCMKTS:FLURF) CEO Danny Dalla-Longa believes that their testing technology is essential for ensuring accurate results for cannabis producers and law enforcement alike.

In the interview below, Dalla-Longa discussed the benefits the Company’s CompleTest™ testing solution which will be disruptive to the industry. He also outlined FluroTech’s future expansion plans into testing for the cannabis and hemp markets in North America and other legal jurisdictions worldwide.

Below is a transcript of our interview with FluroTech CEO Danny Dalla-Longa. It has been edited for clarity and brevity.

Investing News Network: Please give our investor audience an overview of FluroTech and its innovative cannabis testing technologies.

FluroTech CEO Danny Dalla-Longa: The development of FluroTech’s technology began over 10 years ago with Dr. Prenner and the University of Calgary in collaboration with the University of Alberta. It uses existing spectroscopy and fluorescence technology, but manipulated in a different way. We have commenced sales on our plant testing product and we will be moving to our hemp, biomarker and individual testing technology going forward. Our team is in discussions with licensed producers, among others, about the technology. We’re also looking at the hemp industry now that the Farm Bill has passed in the US. It will allow us to move into the market there, as hemp is promising to be a burgeoning market.

INN: What cannabis industry problems is Flurotech trying to solve with its technologies?

DD-L: There’s a problem with the existing cannabis testing technology called cross-lab variability. For instance, the Washington Cannabis Growers Association conducted a test of homogenous samples which was sent to nine different state labs, and which the outcome for was nine different results. The discrepancy can be attributed to the type of technology used and the operator’s testing proficiency.

Our patented technology, however, provides consistent and accurate results. It’s cost-effective, saves time and enables in-house testing. Additionally, it allows growers to “croptomize” their production by continuously testing their crops. For example, a cultivator can test for optimal THC and CBD levels before harvesting, and thus determine which inputs and when best to harvest. They will also be able to double-check their results from the certified lab.

We believe that cross-lab variability will continue. We don’t want to replace certified labs – we want growers to better understand what they have and how to increase yields.

INN: What does it mean to have received Good Manufacturing Practice (GMP) validation for the CompleteTest™ device?

DD-L: Our GMP certification will increase the credibility and adoption of our technology. It also means that down the road LP’s may not need independent verification at certified labs.

INN: Please tell us about your newly announced cocaine testing technology. What are your development plans for this product?

DD-L: Our cocaine testing technology has applications for roadside and industrial testing. We’ve been developing this technology for some time. In industrial testing, our technology will have to detect up to eight different drugs, such as methamphetamine, cocaine, fentanyl and THC, among others.

Roadside testing must be designed to test for three things: THC, cocaine and methamphetamine. The current legal plan in Canada is that, an individual will get tested at his vehicle in order to determine a false positive reading. If that reading is positive, the officer will take the driver to a secondary test to quantify the amount and to confirm the result. Our technology will be employed in this secondary test which doesn’t just give false positive readings but rather a quantification. The federal government is proposing to have a number of suppliers in primary and secondary testing.

We’re also monitoring roadside testing legislation. To date, one supplier has been picked and the lawyers are lined up to litigate this testing protocol on each side. We don’t want to get involved until the litigation clears, therefore, we will focus on industrial testing in the near term as it provides a much larger market opportunity.

INN: What’s next for Flurotech and how does that fit into the company’s long long-term plans?

DD-L: We’ve commenced sales of our products for in-house testing in Canada. We’re also seeking joint venture partners to distribute our testing solution internationally.

We look to penetrate all cannabis and hemp markets and will be developing a test for hemp, a very large market that will allow us to move throughout the US. Once cannabis is legalized federally, we’ll expand our reach State side. Then a move into the European, South American and Caribbean cannabis markets would be our objective as they’ve all seen substantial growth.

We’re also developing a pharma-grade biomarker for extracts and plants that will track cannabis throughout the supply chain. We believe this technology will make current seed-to-sale tracking technology obsolete.

CEO interviews are part of investor education campaigns for clients advertising on the Investing News Network. Important news is contextualized by CEOs, and the resulting interviews are disseminated to the Investing News Network audience because they have value to market watchers.

The Investing News Network interviews a CEO for an understanding of their perspective on the company, the investment potential of the company and market news related to the company. The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. 

Mergers and acquisitions (M&A) in cannabis space have helped boost the industry to new levels.

Keep reading... Show less

Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).

Keep reading... Show less

Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.

Keep reading... Show less

Ensuring estoraTMpatients have seamless access to their high-quality medical cannabis products

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announce that its subsidiary Pineapple Express Delivery Inc. (“Pineapple Express Delivery” or “PED”), a leading logistics technology company offering compliant and secure delivery of controlled substances and regulated products, has partnered with CannTrust Inc. to bring same-day and next-day delivery to estoraTM medical cannabis patients in Ontario

Keep reading... Show less

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less